Fatal hypoglycemia associated with levofloxacin.
Fluoroquinolones are generally regarded as safe antimicrobial agents with relatively few adverse effects or drug interactions. Thus, they enjoy widespread use for treatment of community- and hospital-acquired infections. Although uncommon, hypoglycemia has been reported with all the fluoroquinolones and appears to occur most frequently in elderly patients with type 2 diabetes mellitus who are receiving therapy with oral hypoglycemics. The exact mechanism of this effect is unknown but is postulated to be a result of blockage of adenosine 5'-triphosphate-sensitive potassium channels in pancreatic beta-cell membranes. We report a case of fatal hypoglycemia related to levofloxacin administration in an elderly patient with diabetes. As with other fluoroquinolones, levofloxacin can cause profound and prolonged hypoglycemia. Clinicians should be cognizant of this potential adverse effect in patients with diabetes who are receiving levofloxacin therapy.
Friedrich
Lawrence V
LV
Cubist Pharmaceuticals, Mt. Pleasant, South Carolina, USA. lawrence.friedrich@cubist.com
Dougherty
Richard
R
D000368:Aged; D017809:Fatal Outcome; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D064704:Levofloxacin; D008297:Male; D015242:Ofloxacin / Q000009:adverse effects*
D064704:Levofloxacin; D015242:Ofloxacin